{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-26-000056","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2026-08-06T20:05:37+00:00","discovered_at":"2026-08-06T20:07:10.269219+00:00","generated_at":"2026-08-06T20:07:41.085461+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Maravai Q2 revenue up 8.5% to $51.4M; raises FY2026 Adj EBITDA guidance to $33-35M","bullets":["Q2 revenue $51.4M (+8.5% YoY); net loss narrowed to $(21.6)M from $(69.8)M; Adj EBITDA $8.7M vs $(10.4)M loss.","TriLink revenue $34.7M (+11.5% YoY) driven by Discovery mRNA and GMP consumables; Cygnus $16.8M (+2.8%).","Full year 2026 Adj EBITDA guidance raised to $33M-$35M; revenue guidance reiterated at $205M-$215M.","Opened GMP enzyme manufacturing facility; ModTail product line has 125+ active customers including leading biopharma."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-26-000056","json":"https://secwatch.observer/filing/0001823239-26-000056.json","markdown":"https://secwatch.observer/filing/0001823239-26-000056.md","text":"https://secwatch.observer/filing/0001823239-26-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000056/0001823239-26-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000056/mrvi-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:07:41.085461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}